A Fellow Cancer Survivor Gives Me a Useful Message
A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.
Related Articles
SIRT With 90Y Resin Microspheres Provides Benefit in GIST Liver Metastases
SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver metastases resistant to TKI therapy.
Crafting an Individual Treatment Plan for Patients With Prostate Cancer
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Dr. Eng Breaks Down Braftovi Plus Erbitux FDA Approval in BRAF+ mCRC
Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer.
“Time to talk”? How nurses can acknowledge and respond to men’s mental distress – Evidence-Based Nursing blog
The EBN blog this week is by Nathaniel Smith, (n.smith3@hull.ac.uk) Lecturer in Nursing, in the Faculty of Health Sciences at the University of Hull, UK. …
An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC
The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer.
Northern Ireland urged to fix nurse shortage in special schools | Nursing Times
Read about what Northern Ireland’s Committee for Education was told about the provision of nurses across special schools in the country.
TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups
TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.
First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer
The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.
FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer
The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.
